MCAM (melanoma‐specific cell‐adhesion molecule) has been proved as a novel therapeutic target to overcome chemoresistance through the PI3K/AKT/SOX2 signaling pathway in SCLC (Tripathi et al., 2017). Here, MCAM is linked to small cell lung carcinoma.